Kidnymax Tablet contains Alpha Ketoanalogue (NA), a therapeutic agent primarily indicated for patients with chronic kidney disease (CKD) to help manage metabolic imbalances associated with renal impairment. Alpha Ketoanalogue serves as a nitrogen-free analog of essential amino acids, facilitating protein metabolism while reducing nitrogenous waste accumulation, thereby alleviating the burden on compromised kidneys. This medication is commonly employed as an adjunct to a low-protein diet in CKD stages 3 to 5 to delay the progression of renal dysfunction and minimize uremic symptoms. By providing precursors for amino acid synthesis without contributing to nitrogen load, Kidnymax Tablet supports nutritional status and helps maintain muscle mass in patients with protein-restricted diets. It is crucial to administer this medication under medical supervision, with regular monitoring of renal function, electrolyte levels, and nutritional parameters. Contraindications include hypersensitivity to any component of the formulation. Common adverse effects are generally mild but may include gastrointestinal disturbances such as nausea or constipation. Kidnymax Tablet should be used cautiously in patients with hepatic impairment or metabolic acidosis. Overall, Kidnymax Tablet is a valuable pharmacological option in the multidisciplinary management of CKD to improve patient outcomes and quality of life.